Zentralbl Gynakol 2003; 125(10): 424-429
DOI: 10.1055/s-2003-44484
Original article

© Georg Thieme Verlag Stuttgart · New York

Treatment of Recurrent Epithelial Ovarian Cancer with Secondary Cytoreduction and Continuous Intraoperative Intraperitoneal Hyperthermic Chemoperfusion (CIIPHCP)

Therapie des rezidivierenden epithelialen Ovarialkarzinoms mit sekundärer Tumorreduktion und kontinuierlicher intraoperativer intraperitonealer hyperthermischer Chemoperfusion (CIIPHCP)K. Chatzigeorgiou1 , 2 , S. Economou1 , G. Chrysafis1 , A. Dimasis1 , G. Zafiriou1 , K. Setzis1 , N. Lyratzopoulos2 , G. Minopoulos2 , K. Manolas2 , N. Chatzigeorgiou1
  • 1First Department of Surgical Oncology, Theagenion Cancer Hospital, Thessaloniki, Greece
  • 2First Surgical Clinic, Medical School, Demokritus University of Thrace, Alexandroupolis, Greece
Weitere Informationen


20. November 2003 (online)


Objective: Evaluation of the combined effect of secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP), in the treatment of recurrent ovarian cancer, in a phase II clinical study.
Material and Methods: Twenty consecutive, heavily pre-treated patients with recurrent epithelial ovarian cancer, were treated with a combination of cytoreductive surgery and CIIPHCP. All patients had extended peritoneal carcinomatosis. In 14 out of the 20 pts (70 %) the recurrence occurred during chemotherapy or within 6 months after the end of the chemotherapy. Thirteen pts (65 %) had preoperatively malignant ascites, whereas the remaining seven pts (35 %) had positive peritoneal cytology washings.
Results: No complications emerged during operation and CIIPHCP. Median ascites-free period after CIIPHCP was 21 months (range 3-109). Median survival time for patients with residual disease less than 1.5 cm was 29.0 months, whereas for patients with residual disease equal or greater than 1.5 cm, the median survival time was 7.0 months. This difference was statistically significant (P < 0.05).
Conclusions: The survival data of our patients and the disappearance of the malignant ascites postoperatively suggest that continuous intraoperative intraperitoneal hyperthermic chemoperfusion is an effective treatment option for patients with recurrent ovarian cancer.


Ziel: Auswertung der Kombination aus sekundärer Tumorreduktion und kontinuierlicher intraoperativer intraperitonealer hyperthermischer Chemoperfusion (CIIPHCP) in der Therapie des rezidivierenden Ovarialkarzinoms im Rahmen einer klinischen Studie II. Phase.
Material und Methoden: Zwanzig aufeinanderfolgende, operativ und chemotherapeutisch vorbehandelte Patientinnen mit rezidivierenden epithelialen Ovarialkarzinomen wurden mit einer Kombination aus tumorreduktiver Operation und CIIPHCP behandelt. Alle Patientinnen hatten ausgedehnte Peritonealkarzinome. In 14 von den 20 Patientinnen (70 %) trat das Rezidiv während der Chemotherapie oder innerhalb von sechs Monaten nach dem Ende der Chemotherapie auf. Dreizehn Patientinnen (65 %) hatten malignen Aszites präoperativ, während die übrigen sieben Patientinnen (35 %) positive peritoneale Spülungen aufwiesen.
Ergebnisse: Während der Operation und der CIIPHCP traten keine Komplikationen auf. Das Aszites-freie Intervall betrug 21 Monate (3-109). Die mediane Überlebenszeit für Patientinnen mit Tumorrest weniger als 1,5 cm war 29,0 Monate, wobei für Patientinnen mit Tumorrest gleich oder größer als 1,5 cm die mediane Überlebenszeit 7,0 Monate betrug. Dieser Unterschied war statistisch signifikant (P < 0,05).
Schlussfolgerungen: Die Überlebensdaten unserer Patientinnen und das postoperative Verschwinden des malignen Aszites deutet an, dass die kontinuierliche intraoperative intraperitoneale hyperthermische Chemoperfusion eine effektive therapeutische Option für Patientinnen mit rezidivierenden Ovarialkarzinomen darstellt.


  • 1 Armstrong D K. Relapsed ovarian cancer: Challenges and management strategies for a chronic disease.  The Oncologist. 2002;  7 (Suppl 5) 20-28
  • 2 Begossi G, Gonzalez-Moreno S, Ortega-Perez G, Fon L J, Sugarbaker P H. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.  Eur J Surg Oncol. 2002;  28 80-87
  • 3 Cavaliere F, Perri P, Di Filippo F. et al . Treatment of peritoneal carcinomatosis with intent to cure.  J of Surg Oncol. 2000;  74 41-44
  • 4 Ceelen W P, Hesse U, de Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra- abdominal cancer.  Br J Surg. 2000;  87 1006-1015
  • 5 Chatzigeorgiou K, Economou S, Zafiriou G, Minopoulos G, Manolas K, Chatzigeorgiou N. Continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP) in the treatment of advanced stage and recurrent granulosa cell tumors. Report of two cases.  Zentralbl Gynakol. 2002;  124 374-377
  • 6 Chen L M, Karlan B Y. Recurrent ovarian carcinoma: Is there a place for surgery?.  Sem Surg Oncol. 2000;  19 62-68
  • 7 Clamp A, Jayson G C. Weekly platinum chemotherapy for recurrent ovarian cancer (Editorial).  British J Cancer. 2002;  86 2-4
  • 8 Deraco M, Rossi C R, Pennacchioli E. et al . Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study.  Tumori. 2001;  87 20-126
  • 9 De Simone M, Sperone P, Scuderi S, Costamagna D. et al .Cytoreductive surgery followed by intraperitoneal hyperthermic antiblastic perfusion in the treatment of abdominal recurrence of ovarian cancer. ASCO 2002; Abstract 2515
  • 10 Di Filippo F, Anzà M, Rossi C R. et al . The application of hyperthermia in regional chemotherapy.  Sem Surg Oncol. 1998;  14 215-223
  • 11 Fung M F, Johnston M E, Eisenhauer E A, Elit L, Hirte H W, Rosen B. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum - a systemic review of the evidence from randomized trials.  Eur J Gynaecol Oncol. 2002;  23 104-110
  • 12 Hager E, Dziambor H, Hohmann D, Muhe N, Strama H. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy- resistant peritoneal disseminated ovarian cancer.  Int J Gynecol Cancer. 2001;  11 57-63
  • 13 Iitsuka Y, Kaneshima S, Tanida O. Intraperitoneal free cancer cells and their viability in gastric cancer.  Cancer. 1979;  44 1476-1480
  • 14 Kober F, Heiss A, Roka R. Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion.  Cancer Treat Res. 1996;  82 211-219
  • 15 Kuhn W C. Therapy for recurrent ovarian cancer.  Curr Womens Health Rep. 2003;  3 33-38
  • 16 Kuzuya T, Yamauchi M, Ito A. et al . Pharmacokinetic characteristics of 5-Fluorouracil and Mitomycin C in intraperitoneal chemotherapy.  J Pharm Pharmacol. 1994;  46 685-689
  • 17 Loggie B W, Fleming R A, McQuellon R P. et al . Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin.  Am Surg. 2000;  66 561-568
  • 18 Lopes Cardoso A MF, Gupta A, Koppe M J, Meijer S, van Leeuwen P AM, Beelen R JH. et al . Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats.  Eur J Surg Oncol. 2001;  27 359-363
  • 19 Markman M. Intraperitoneal chemotherapy in the management of malignant disease.  Expert Rev Anticancer Ther. 2001;  1 142-148
  • 20 Markman M, Brady M F, Spirtos N M. et al . Phase II trial of intraperitoneal Paclitaxel in carcinoma of the ovary, tube and peritoneum: a Gynecologic Oncology Group Study.  J Clin Oncol. 1998;  16 2620-2624
  • 21 McCarter M D, Fong Y. Role for surgical cytoreduction in multimodality treatments for cancer.  Ann Surg Oncol. 2001;  8 38-43
  • 22 Pilati P, Rossi C R, Mocellin S, Foletto M, Scagnet B, Pasetto L, Lise M. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis.  Eur J Surg Oncol. 2001;  27 125-134
  • 23 Piso P, Bektas H, Werner U. et al . Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma.  Eur J Surg Oncol. 2001;  27 286-290
  • 24 Samel S, Singal A, Becker H, Post S. Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer.  Eur J Surg Oncol. 2000;  26 222-226
  • 25 Shido A, Ohmura S, Yamamoto K. et al . Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion?.  World J Surg. 2000;  24 507-511
  • 26 Sijmons E A, Heintz P M. Second-look and second surgery: Second chance or second best.  Sem Surg Oncol. 2000;  19 54-61
  • 27 Spencer C M, Ga K L. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.  Drugs. 1995;  50 1001-1031
  • 28 Steller M A, Egorin M J, Trimble E L. et al . A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small- volume residual ovarian cancer.  Cancer Chemother Pharmacol. 1999;  43 106-114
  • 29 Stephens A D, Alderman R, Chang D. et al . Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique.  Ann Surg Oncol. 1999;  6 790-796
  • 30 van de Vaart P JM, van der Vange N, Zoetmulder F AN. et al . Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.  Eur J Cancer. 1998;  34 148-154
  • 31 van der Vange N, van Goethem A R, Zoetmulder F AN. et al . Extensive cytoreductive surgery combined with intra- operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.  Eur J Surg Oncol. 2000;  26 663-668

Konstantinos Chatzigeorgiou

85 Dimokratias Str.

55236 Panorama


Telefon: +30 23 10 81 50 80

Telefon: +30 23 10 34 34 85

Fax: +30 23 10 54 45 85

eMail: chatzkon@hotmail.com